SH2 domain-containing inositol 5-phosphatase (SHIP2) regulates de-novo lipogenesis and secretion of apoB100 containing lipoproteins in HepG2 cells

Biochemical and Biophysical Research Communications

Volumn 464, Issue 4, 2015, Pages 1028-1033

  Gorgani Firuzjaee, Sattar ^a   Khatami, Shohreh ^b   Adeli, Khosrow ^c   Meshkani, Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

De novo lipogenesis; HepG2; Insulin resistance; Liver; SH2 domain containing inositol 5 phosphatase (SHIP2); VLDL

Indexed keywords

ACYL COENZYME A; APOLIPOPROTEIN B100; FAS ANTIGEN; OLEIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SH2; SH2 DOMAIN CONTAINING INOSITOL 5 PHOSPHATASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ACYL-COA CARBOXYLASE; INPPL1 PROTEIN, HUMAN; INSULIN; LIGASE; PHOSPHATASE; SREBF1 PROTEIN, HUMAN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; HEPG2 CELL LINE; LIPOGENESIS; LIPOPROTEIN METABOLISM; LIPOPROTEIN SECRETION; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DYSLIPIDEMIAS; GENETICS; HUMAN; LIVER CELL; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

APOLIPOPROTEIN B-100; CARBON-CARBON LIGASES; DYSLIPIDEMIAS; GENE EXPRESSION; HEP G2 CELLS; HEPATOCYTES; HUMANS; INSULIN; LIPOGENESIS; OLEIC ACID; PHOSPHORIC MONOESTER HYDROLASES; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84940461225     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.07.059     Document Type: Article

References (33)

1. C. Day Metabolic syndrome, or what you will: definitions and epidemiology Diabetes Vasc. Dis. Res. 4 2007 32 38
2. G. Taheripak, S. Bakhtiyari, M. Rajabibazl, P. Pasalar, and R. Meshkani Protein tyrosine phosphatase 1B inhibition ameliorates palmitate-induced mitochondrial dysfunction and apoptosis in skeletal muscle cells Free Radic. Biol. Med. 65 2013 1435 1446
3. R. Meshkani, and K. Adeli Hepatic insulin resistance, metabolic syndrome and cardiovascular disease Clin. Biochem. 42 2009 1331 1346
4. S.M. Grundy Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance Clin. Cornerstone 8 2006 S21 S27
5. M. Adiels, J. Borén, M.J. Caslake, P. Stewart, A. Soro, J. Westerbacka, B. Wennberg, S.-O. Olofsson, C. Packard, and M.-R. Taskinen Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia Arterioscler. Thromb. Vasc. Biol. 25 2005 1697 1703
6. M. Arca, G. Pigna, and C. Favoccia Mechanisms of diabetic dyslipidemia: relevance for atherogenesis Curr. Vasc. Pharmacol. 10 2012 684 686
7. K.G. Sidiropoulos, R. Meshkani, R. Avramoglu-Kohen, and K. Adeli Insulin inhibition of apolipoprotein B mRNA translation is mediated via the PI-3 kinase/mTOR signaling cascade but does not involve internal ribosomal entry site (IRES) initiation Arch. Biochem. Biophys. 465 2007 380 388
8. J. Sparks, T. Phung, M. Bolognino, and C. Sparks Insulin-mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation: studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes Biochem. J. 313 1996 567 574
9. A.-M. Brown, and G.F. Gibbons Insulin inhibits the maturation phase of VLDL assembly via a PHOSPHOINOSITIDE 3-kinase - mediated event Arterioscler. Thromb. Vasc. Biol. 21 2001 1656 1661
10. R.V. Farese, M.P. Sajan, and M.L. Standaert Insulin-sensitive protein kinases (atypical protein kinase C and protein kinase B/Akt): actions and defects in obesity and type II diabetes Exp. Biol. Med. 230 2005 593 605
11. A.D. Cristofano, B. Pesce, C. Cordon-Cardo, and P.P. Pandolfi Pten is essential for embryonic development and tumour suppression Nat. Genet. 19 1998 348 355
12. S. Giuriato, X. Pesesse, S. Bodin, T. Sasaki, C. Viala, E. Marion, J. Penninger, S. Schurmans, C. Erneux, and B. Payrastre SH2-containing inositol 5-phosphatases 1 and 2 in blood platelets: their interactions and roles in the control of phosphatidylinositol 3, 4, 5-trisphosphate levels Biochem. J. 376 2003 199 207
13. M. Vinciguerra, and M. Foti PTEN and SHIP2 phosphoinositide phosphatases as negative regulators of insulin signalling Arch. Physiol. Biochem. 112 2006 89 104
14. H. Ishihara, T. Sasaoka, H. Hori, T. Wada, H. Hirai, T. Haruta, W.J. Langlois, and M. Kobayashi Molecular cloning of rat SH2-containing inositol phosphatase 2 (SHIP2) and its role in the regulation of insulin signaling Biochem. Biophys. Res. Commun. 260 1999 265 272
15. M.W. Sleeman, K.E. Wortley, K.-M.V. Lai, L.C. Gowen, J. Kintner, W.O. Kline, K. Garcia, T.N. Stitt, G.D. Yancopoulos, and S.J. Wiegand Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity Nat. Med. 11 2005 199 205
16. H. Hori, T. Sasaoka, H. Ishihara, T. Wada, S. Murakami, M. Ishiki, and M. Kobayashi Association of SH2-containing inositol phosphatase 2 with the insulin resistance of diabetic db/db mice Diabetes 51 2002 2387 2394
17. S. Gorgani-Firuzjaee, S. Ahmadi, and R. Meshkani Palmitate induces SHIP2 expression via the ceramide-mediated activation of NF-κB, and JNK in skeletal muscle cells Biochem. Biophys. Res. Commun. 450 2014 494 499
18. T. Wada, T. Sasaoka, M. Funaki, H. Hori, S. Murakami, M. Ishiki, T. Haruta, T. Asano, W. Ogawa, and H. Ishihara Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5′-phosphatase catalytic activity Mol. Cell. Biol. 21 2001 1633 1646
19. R. Grempler, D. Zibrova, C. Schoelch, A. van Marle, J.F. Rippmann, and N. Redemann Normalization of prandial blood glucose and improvement of glucose tolerance by liver-specific inhibition of SH2 domain-containing inositol phosphatase 2 (SHIP2) in diabetic KKAy mice SHIP2 inhibition causes insulin-mimetic effects on glycogen metabolism, gluconeogenesis, and glycolysis Diabetes 56 2007 2235 2241
20. S. Kagawa, Y. Soeda, H. Ishihara, T. Oya, M. Sasahara, S. Yaguchi, R. Oshita, T. Wada, H. Tsuneki, and T. Sasaoka Impact of transgenic overexpression of SH2-containing inositol 5′-phosphatase 2 on glucose metabolism and insulin signaling in mice Endocrinology 149 2008 642 650
21. S. Cabaro, A. Liotti, M. Longo, L. Parrillo, T.B. Pagano, G.A. Raciti, D. Penkov, O. Paciello, C. Miele, and P. Formisano PREP1 deficiency downregulates hepatic lipogenesis and attenuates steatohepatitis in mice Diabetologia 56 2013 2713 2722
22. S. Kagawa, T. Sasaoka, S. Yaguchi, H. Ishihara, H. Tsuneki, S. Murakami, K. Fukui, T. Wada, S. Kobayashi, and I. Kimura Impact of SRC homology 2-containing inositol 5′-phosphatase 2 gene polymorphisms detected in a Japanese population on insulin signaling J. Clin. Endocrinol. Metabol. 90 2005 2911 2919
23. S. Gorgani-Firuzjaee, K. Adeli, and R. Meshkani Inhibition of SH2 domain containing inositol 5-phosphatase (SHIP2) ameliorates palmitate induced-apoptosis through regulating Akt/FOXO1 pathway and ROS production in HepG2 cells Biochem. Biophys. Res. Commun. 464 2 2015 441 446 10.1016/j.bbrc.2015.06.134
24. J. Zhang, Z. Liu, J. Rasschaert, D. Blero, L. Deneubourg, S. Schurmans, C. Erneux, and X. Pesesse SHIP2 controls PtdIns (3, 4, 5) P 3 levels and PKB activity in response to oxidative stress Cell. Signal. 19 2007 2194 2200
25. H.N. Ginsberg Treatment for patients with the metabolic syndrome Am. J. Cardiol. 91 2003 29 39
26. D.E. Moller, and K.D. Kaufman Metabolic syndrome: a clinical and molecular perspective Annu. Rev. Med. 56 2005 45 62
27. R.K. Avramoglu, H. Basciano, and K. Adeli Lipid and lipoprotein dysregulation in insulin resistant states Clin. Chim. Acta 368 2006 1 19
28. M.A. den Boer, P.J. Voshol, F. Kuipers, J.A. Romijn, and L.M. Havekes Hepatic glucose production is more sensitive to insulin-mediated inhibition than hepatic VLDL-triglyceride production Am. J. Physiol. Endocrinol. Metabol. 291 2006 E1360 E1364
29. A. Kamagate, S. Qu, G. Perdomo, D. Su, D.H. Kim, S. Slusher, M. Meseck, and H.H. Dong FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice J. Clin. Invest. 118 2008 2347 2364
30. W. Qiu, R.K. Avramoglu, N. Dubé, T.M. Chong, M. Naples, C. Au, K.G. Sidiropoulos, G.F. Lewis, J.S. Cohn, and M.L. Tremblay Hepatic PTP-1B expression regulates the assembly and secretion of apolipoprotein B-containing lipoproteins evidence from protein tyrosine phosphatase-1B overexpression, knockout, and RNAi studies Diabetes 53 2004 3057 3066
31. P. Ferre, and F. Foufelle Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c, Diabetes Obes. Metabol. 12 2010 83 92
32. J.D. Sparks, and C.E. Sparks Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes J. Biol. Chem. 265 1990 8854 8862
33. T.L. Phung, A. Roncone, K.L. de Mesy Jensen, C.E. Sparks, and J.D. Sparks Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum J. Biol. Chem. 272 1997 30693 30702